1 / 9

Prof. Dr. W.-H. Boehncke Dept. of Dermatology Johann Wolfgang Goethe-University Frankfurt/Main

measuring QOL in psoriasis: status quo . Prof. Dr. W.-H. Boehncke Dept. of Dermatology Johann Wolfgang Goethe-University Frankfurt/Main. the instruments. DLQI most widely used SF-36 other approaches EuroQoL 5D (EQ-5D) „self-made“ questionnaires focus on self- esteem etc.

betty
Download Presentation

Prof. Dr. W.-H. Boehncke Dept. of Dermatology Johann Wolfgang Goethe-University Frankfurt/Main

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. measuring QOL in psoriasis: status quo  Prof. Dr. W.-H. Boehncke Dept. of Dermatology Johann Wolfgang Goethe-University Frankfurt/Main

  2. the instruments • DLQI • most widely used • SF-36 • other approaches • EuroQoL 5D (EQ-5D) • „self-made“ questionnaires • focus on self- esteem etc.

  3. Psoriasis is Third only to Chronic Lung Disease and Depression When Considering the Mental Impact of the Disease1 60 50 40 Mean Score 30 20 10 0 Cancer Arthritis Psoriasis Dermatitis Depression Congestive Heart Failure Hypertension Healthy Adults Chronic Lung Disease Myocardial Infarction Type 2 Diabetes Reference: 1. Rapp SR et al. J Am Acad Dermatol 1999; 41: 401–7.

  4. Psoriasis is Second only to CHF When Considering the Physical Impact of the Disease1 60 50 40 Mean score 30 20 10 0 Cancer Psoriasis Arthritis Dermatitis Congestive heart failure Depression Myocardial infarction Hypertension Healthy adults Chronic lung disease Type 2 diabetes Reference: 1. Rapp SR et al. J Am Acad Dermatol 1999; 41: 401–7.

  5. the results • robust finding: instruments measuring QOL indicate improvement when the disease is treated effectively

  6. Placebo 80 ‡ 70% ENBREL* 25 mg BiWk 70 ENBREL 50 mg BiWk 65% 60 ‡ ‡ 50 Mean % Improvement From Baseline 40 ‡ 30 20 10 0 2 0 4 8 12 Weeks Patient Quality of Life Significantly Improved within 2 Weeks1,2 ‡ ‡ ‡ * 6% *P = 0.0002 vs placebo ‡P < 0.0001 vs placebo References 1.van der Kerkhof PCN et al. ESDR 2004 abstract. 2.Data on file, Amgen, Thousand Oaks, Calif.

  7. the problem • Is there a correlation between the „objective“ clinical course and QOL? • Answer • The DLQI „…demonstrated the ability to detect small but meaningful changes in clinical status over time…“ Mazzotti et al., BJD 2003, 149: 318 • „DLQI and PASI improve together initially and during retreatment with etanercept“ Leonardi et al., AAD and EADV posters 2005 ???

  8. the „but“ • All it takes to „earn“ >105 € worth of treatment is to know where to put your marks on a questionnaire!!!

  9. a solution? participation

More Related